Assessing KalVista Pharmaceuticals (KALV) Valuation After Strong Recent Share Price Momentum

Simply Wall St.05-17 11:33

AdvertisementRecent stock performance context for KalVista Pharmaceuticals KalVista Pharmaceuticals (KALV) has drawn fresh attention after a strong share price move, with the stock up about 31% over ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636095886?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-17 11:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636095886","market":"nz","top_or_hot":-1,"title":"Assessing KalVista Pharmaceuticals (KALV) Valuation After Strong Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent stock performance context for KalVista Pharmaceuticals KalVista Pharmaceuticals (KALV) has drawn fresh attention after a strong share price move, with the stock up about 31% over ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/assessing-kalvista-pharmaceuticals-kalv-valuation-after-stro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing KalVista Pharmaceuticals (KALV) Valuation After Strong Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing KalVista Pharmaceuticals (KALV) Valuation After Strong Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-17 11:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/assessing-kalvista-pharmaceuticals-kalv-valuation-after-stro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent stock performance context for KalVista Pharmaceuticals KalVista Pharmaceuticals (KALV) has drawn fresh attention after a strong share price move, with the stock up about 31% over ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/assessing-kalvista-pharmaceuticals-kalv-valuation-after-stro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/assessing-kalvista-pharmaceuticals-kalv-valuation-after-stro","article_id":"2636095886","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kalv/kalvista-pharmaceuticals/news/assessing-kalvista-pharmaceuticals-kalv-valuation-after-stro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636095886","pubTimestamp":1778988796,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent stock performance context for KalVista Pharmaceuticals\nKalVista Pharmaceuticals (KALV) has drawn fresh attention after a strong share price move, with the stock up about 31% over the past month and roughly 79% over the past 3 months.\nSee our latest analysis for KalVista Pharmaceuticals.\nThat recent surge sits on top of a much stronger long-term picture, with a 1-year total shareholder return of 124.06% and a 3-year total shareholder return of 153.85%, signalling firm upward momentum...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KALV":"Kalvista Pharmaceuticals Inc"},"translate_title":"在近期股价强劲势头后评估KalVista Pharmaceuticals(KALV)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":1.5},"content_text":"AdvertisementRecent stock performance context for KalVista Pharmaceuticals KalVista Pharmaceuticals (KALV) has drawn fresh attention after a strong share price move, with the stock up about 31% over the past month and roughly 79% over the past 3 months. See our latest analysis for KalVista Pharmaceuticals. That recent surge sits on top of a much stronger long-term picture, with a 1-year total shareholder return of 124.06% and a 3-year total shareholder return of 153.85%, signalling firm upward momentum around KalVista Pharmaceuticals. If rapid price moves in biotech interest you, this is a good moment to broaden your watchlist and check out 32 healthcare AI stocks With KalVista Pharmaceuticals now trading close to its analyst price target and carrying an implied intrinsic discount, the key question is whether the recent surge still leaves mispricing on the table or whether markets already reflect future growth. Most Popular Narrative: 13.8% Undervalued KalVista Pharmaceuticals' most followed narrative points to a fair value of $31.00 per share, compared with the latest close at $26.73, putting the current rally in a broader context.  Early EKTERLY uptake in high burden hereditary angioedema patients, reflected in 937 U.S. start forms within roughly 4 months and refill patterns more frequent than historical injectable on demand therapies, points to a treatment shift that could support higher on demand prescription volumes and revenue per patient.  Read the complete narrative. Want to understand why this fair value sits above today’s price? The narrative leans heavily on rapid revenue expansion, margin improvement and a rich future earnings multiple. The real story is in how those pieces fit together. Result: Fair Value of $31.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there is still a risk that EKTERLY demand normalizes below early high burden usage and that payer limits or step requirements constrain future paid prescription volumes. Find out about the key risks to this KalVista Pharmaceuticals narrative. Next Steps With sentiment split between strong upside potential and clear risks, this is a moment to look through the numbers yourself and decide quickly where you stand. You can start with 2 key rewards and 2 important warning signs Looking for more investment ideas? If you stop with just one stock, you could miss opportunities that fit your goals even better, so put a few strong alternatives on your radar today.  Target higher quality opportunities by scanning for companies trading below estimated value with solid fundamentals using the 51 high quality undervalued stocks. Prioritize income potential by reviewing companies offering yields above 5% and consistent payouts through the 13 dividend fortresses. Reduce surprise risk by focusing on companies with stronger balance sheets and healthier fundamentals via the solid balance sheet and fundamentals stocks screener (45 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if KalVista Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636095886","isCrawlerRequest":true}